Profile data is unavailable for this security.
About the company
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.
- Revenue in CAD (TTM)293.41k
- Net income in CAD-2.15m
- Incorporated2017
- Employees--
- LocationWaverley Pharma Inc4-1250 Waverley StWINNIPEG R3T 6C6CanadaCAN
- Phone+1 (204) 928-7907
- Fax+1 (204) 453-1370
- Websitehttps://www.waverleypharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hempshire Group Inc | 271.25k | -3.43m | 1.19m | -- | -- | -- | -- | 4.40 | -0.0431 | -0.0431 | 0.0034 | -0.003 | 0.1424 | 0.2852 | 29.30 | -- | -180.18 | -- | -288.91 | -- | 46.93 | -- | -1,265.05 | -- | 0.0712 | -21.61 | 1.61 | -- | -68.89 | -- | -200.59 | -- | -- | -- |
| Waverley Pharma Inc | 293.41k | -2.15m | 1.35m | -- | -- | -- | -- | 4.60 | -0.0398 | -0.0398 | 0.0054 | -0.0259 | 0.1759 | -- | 2.33 | -- | -128.84 | -32.30 | -- | -60.75 | 26.58 | 13.74 | -732.29 | -94.30 | -- | -11.66 | 5.43 | -- | -66.95 | 13.03 | -234.91 | -- | -- | -- |
| Vaxil Bio Ltd | 0.00 | -188.00k | 1.37m | -- | -- | 1.64 | -- | -- | -0.0014 | -0.0014 | 0.00 | 0.0061 | 0.00 | -- | -- | -- | -16.28 | -65.45 | -20.26 | -116.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.51 | -- | -- | -- |
| Solarvest Bioenergy Inc | 520.00 | -1.72m | 1.52m | -- | -- | -- | -- | 2,920.93 | -0.0289 | -0.0289 | 0.00001 | -0.097 | 0.0005 | -- | 0.0301 | -- | -177.23 | -95.33 | -- | -3,099.07 | 57.69 | -- | -330,076.90 | -75,194.81 | -- | -8.39 | -- | -- | -4.85 | -- | -48.35 | -- | 1.70 | -- |
